$271.550
-2.037 (-0.75%)Zum Schluss
IQV-News
IQV-Events
IQVIA Reports Q3 Revenue of $4.428B
Reports Q3 revenue $4.428B, consensus $4.37B. "IQVIA delivered another record quarter, with revenue, Adjusted EBITDA and Adjusted Diluted EPS all exceeding the high end of our expectations," said Ari Bousbib, chairman and CEO of IQVIA. "Multiple demand indicators continue to validate the strengthening market environment. EBP funding, RFP flow, clinical trial starts, FDA approvals, outsourcing trends, and pipeline growth across clinical and commercial are all favorable. At the same time, the team's ongoing excellent execution delivered margin expansion, strong free cash flow, higher win rates that resulted in our strongest clinical quarterly bookings since 2022, increased penetration of AI-powered solutions with over 400 AI agents deployed to date, and organic growth acceleration year-over-year to double the rate for commercial and nearly triple the rate for clinical."
Sees FY26 Revenue at $17.35B-$17.5B
Sees FY26 revenue $17.35B-$17.5B, consensus $17.42B
IQVIA and Veeva Expand Partnership
IQVIA (IQV) and Veeva Systems (VEEV) announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies. This extends the previously announced EDC partnership. "This is an exciting expansion of the partnership IQVIA and Veeva announced last year and the work we have done together since," said Veeva founder and CEO Peter Gassner. "We are committed to supporting seamless product and services integration for the benefit of our customers and improving access to innovations for patients."
Iqvia Launches Life Science Models to Predict Clinical Trial Outcomes
Iqvia (IQV) introduced Iqvia Life Science Models to help predict clinical trial outcomes. Iqvia Life Science Models are a suite of purpose-built models for life sciences, combining Iqvia's proprietary expert content, deep domain knowledge and established regulatory, compliance and privacy frameworks. Built using technologies including Nvidia (NVDA) Nemotron and supported by Amazon Web Services (AMZN) infrastructure, the models connect molecular and treatment information with patient journeys and clinical outcomes to enable predictive applications across clinical development.
Iqvia Launches Iqvia Explorer to Enhance Commercial Decision-Making
Iqvia introduced Iqvia Explorer to help customers make better-informed commercial decisions. Iqvia Explorer turns complex, one-time analytics projects into an always-on commercial intelligence capability. Users can apply external indicators and ask business questions, and Explorer brings together the relevant Iqvia data, analytical methods and workflows to provide near real-time intelligence to support decision-making. This allows teams to identify opportunities sooner, improve execution and make faster, more informed decisions that drive commercial performance and ROI. "In a market defined by complexity, volatility and margin compression, improving productivity requires commercial teams to respond faster to change, execute more efficiently and deliver stronger business outcomes," said Pete Groves, EVP, AI & Technology Solutions at Iqvia. "Our customers trust IQVIA's data foundation and advanced analytical capabilities to understand performance today and model what may happen tomorrow. IQVIA Explorer does both, in a matter of minutes."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.